← Eichor
Study identifier: NCT03885635 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hemiarch vs Extended Arch in Type 1 Aortic Dissection

Condition: Aortic Dissection  ·  Sponsor: Ottawa Heart Institute Research Corporation

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

HEADSTART is a prospective, open-label, non-blinded, multicenter, randomized controlled trial that compares a composite of mortality and re-intervention in patients undergoing hemiarch and extended arch repair for acute DeBakey type 1 aortic dissection. Eligible patients will be randomized to one or the other surgical strategy and clinical and imaging outcome data will be collected over a 3 year follow up period.

This description comes directly from the study's public registry record.

Talk to the study team

Khatira Mehdiyeva  ·  613-696-7000  ·  kmehdiyeva@ottawaheart.ca

Alice Black  ·  403-389-8958  ·  AlBlack@ottawaheart.ca

Always discuss trial participation with your own doctor first.

Locations (4)

London Health Sciences CentreLondon, Ontario, CanadaRecruiting
University Health NetworkToronto, Ontario, CanadaRecruiting
Montreal Heart InstituteMontreal, Quebec, CanadaRecruiting
Institut Universitaire De Cardiologie Et De Pneumologie de QuébecQuébec, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03885635